Viral variants and methods for detecting same

ABSTRACT

The present invention relates generally to viral variants exhibiting reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B variants exhibiting complete or partial resistance to nucleoside analogs and/or reduced interactivity with antibodies to viral surface components. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic agents.

This application is a divisional of Ser. No. 12/117,869 (pending), filed May 9, 2008 (published as US 2010-0203506-A1), which is a continuation of Ser. No. 10/260,451 (abandoned), filed Oct. 1, 2002 (published as US 2003-0124096-A1), which is a divisional of Ser. No. 09/306,420, filed May 6, 1999 (issued as U.S. Pat. No. 6,555,311), which is a U.S. national phase of PCT/AU97/00520, filed Aug. 15, 1997, which claims benefit of Australian Application No. PO 3519, filed Nov. 8, 1996, the entire contents of each of which are hereby incorporated by reference.

The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B variants exhibiting complete or partial resistance to nucleoside analogues and/or reduced interactivity with antibodies to viral surface components. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic regimes.

Bibliographic details of the publications numerically referred to in this specification are collected at the end of the description. Sequence Identity Numbers (SEQ ID NOs.) for the nucleotide and amino acid sequences referred to in the specification are defined following the bibliography.

Throughout this specification, unless the context requires otherwise, the word “comprise”, or variations such as “comprises” or “comprising” or the term “includes” or variations thereof, will be understood to imply the inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers. In this regard, in construing the claim scope, an embodiment where one or more features is added to any of claim is to be regarded as within the scope of the invention given that the essential features of the invention as claimed are included in such an embodiment.

Specific mutations in an amino acid sequence are represented herein as AXaa₁nXaa₂″ where Xaa₁ is the original amino acid residue before mutation, n is the residue number and Xaa₂ is the mutant amino acid. The abbreviation “Xaa” may be the three letter or single letter amino acid code. The amino acid residues for Hepatitis B virus DNA polymerase are numbered with the residue methionine in the motif Tyr Met Asp Asp (YMDD) being residue number 550. In the priority document, Australian Patent Application No. PO3519, filed 8 Nov. 1996, the same methionine was designated residue 530. The amino acid residues for the DNA polymerase referred to in this specification have been re-numbered accordingly.

Hepatitis B Virus (HBV) can cause debilitating disease conditions and can lead to acute liver failure. HBV is a DNA virus which replicates via an RNA intermediate and utilizes reverse transcription in its replication strategy (1). The HBV genome is of a complex nature having a partially double stranded DNA structure with overlapping open reading frames encoding surface, core, polymerase and X genes. The complex nature of the HBV genome is represented in FIG. 1.

The presence of an HBV DNA polymerase has led to the proposition that nucleoside analogues could act as effective anti-viral agents. Examples of nucleoside analogues currently being tested are penciclovir and its oral form famciclovir (2, 3, 4, 5) and lamivudine (6,7). There is potential for such agents to be used in the treatment of chronic HBV infection.

Peniciclovir has been recently shown to have potent inhibitory activity against duck HBV DNA synthesis in vitro and has been shown to inhibit HBV DNA polymerase-reverse transcriptase activity in vitro (8,9). Similarly, oral famiciclovir has been demonstrated to inhibit intra-hepatic replication of duck HBV virus in vivo (10). In man, famciclovir has been shown to reduce HBV DNA replication in a patient with severe hepatitis B following orthotopic liver transplantation (OLT) (11).

In work leading up to the present invention, nucleoside analogue antiviral therapy was used to control severe post-OLT recurrence of HBV infection (12). Long term therapy is mandatory where patients are immunosuppressed and the rate of HBV replication is very high. However, under such conditions, as with any long term chemotherapy of infectious agents, there is a potential for development of resistance or reduced sensitivity to the therapeutic agents employed.

In accordance with the present invention, the inventors have identified variants of HBV with mutations in the HBV DNA polymerase gene which to varying extents reduce the sensitivity of HBV to nucleoside analogues. The identification of these HBV variants is important for the development of assays to monitor nucleoside analogue therapeutic regimes and to screen for agents which can mask the effects of the mutation. In addition, since the HBV genome comprises a series of overlapping open reading frames, a nucleotide mutation in one open reading frame can affect translation products in another open reading frame. In further accordance with the present invention, the inventors have observed mutations which reduce the interactivity of immunological reagents, such as antibodies and immune cells, to viral surface components. Such viral variants are referred to herein as “escape mutants” since they potentially escape existing immunological memory.

Accordingly, one aspect of the present invention is directed to a variant of an isolated DNA virus which replicates via an RNA intermediate wherein said variant comprises a nucleotide mutation in a gene encoding a DNA polymerase resulting in at least one amino acid addition, substitution and/or deletion to said DNA polymerase.

Another aspect of the present invention provides a variant of an isolated DNA virus which replicates via an RNA intermediate wherein said variant comprises a nucleotide mutation in a gene encoding a viral surface component resulting in at least one amino acid addition, substitution and/or deletion in said viral surface component.

Still a further aspect of the present invention is directed to a variant of an isolated DNA virus which replicates via an RNA intermediate at least wherein said variant comprises a nucleotide mutation in an overlapping portion of at least two open reading frames resulting in an amino acid addition, substitution and/or deletion to translation products of said open reading frames.

Preferably, the DNA virus is a hepatitis virus or a related virus and is most preferably HBV.

A “related virus” in accordance with the present invention is one related at the genetic, immunological, epidemiological and/or biochemical levels.

Preferably, the mutation in the DNA polymerase results in decreased sensitivity of the HBV to a nucleoside analogue.

Preferably, the mutation in the viral surface component reduces the interactivity of immunological reagents such as antibodies and immune cells to the viral surface component. Most preferably, the viral surface component is a viral surface antigen. The reduction in the interactivity of immunological reagents to a viral surface component generally includes the absence of immunological memory to recognise or substantially recognise the viral surface component.

A viral variant may, in accordance with a preferred aspect of the present invention, carry mutation only in the DNA polymerase or the surface antigen or may carry a mutation in both molecules. The term “mutation” is to be read in its broadest context and includes a silent mutation not substantially affecting the normal function of the DNA polymerase or surface antigen or may be an active mutation having the effect of inducing nucleoside analogue resistance or an escape mutant phenotype. Where multiple mutations occur in accordance with the present invention or where multiple phenotypes result from a single mutation, at least one mutation must be active or the virus must exhibit at least one altered phenotype such as nucleoside analogue resistance or reduced immunological interactivity to the surface antigen.

Regions of the HBV polymerase show amino acid similarity with other RNA-dependent DNA polymerases and RNA-dependent polymerases (13). In this specification, reference is made to the conserved regions defined by Poch et al (13) as domains B and C.

Preferably, the mutation results in an altered amino acid sequence in the B domain and/or C domain or regions proximal thereto of the HBV DNA polymerase. The present invention does not extend to a mutation alone in the YMDD motif of the C domain of the HBV DNA polymerase although such a mutation is contemplated by the present invention if it occurs in combination with one or more mutations in another location.

The mutation in the viral surface component is preferably in one or more amino acid residues within the major hydrophilic regions of the protein, in particular within the amino acid sequence 118-169 of the HBV viral surface antigen and also the regions from amino acids sequence 169 to 207 which are on the external surface of the protein.

According to a preferred aspect of the present invention, there is provided an HBV variant comprising a mutation in the nucleotide sequence encoding a DNA polymerase resulting in an amino acid addition, substitution and/or deletion in said DNA polymerase in its B domain and/or C domain or in a region proximal thereto, provided said mutation is not in the YMDD motif of the C domain alone, and wherein said variant exhibits decreased sensitivity to a nucleoside analogue.

Another preferred aspect of the present invention contemplates an HBV variant comprising a mutation in the nucleotide sequence encoding a viral surface component resulting in an amino acid addition, substitution and/or deletion in said viral surface component in a region corresponding to the B domain and/or C domain of HBV DNA polymerase or a region proximal to the B domain and/or C domain of HBV DNA polymerase and wherein said variant exhibits decreased interactivity of immunological reagents to said viral surface component.

Yet another preferred aspect of the present invention relates to an HBV variant comprising a mutation in the nucleotide sequence encoding a viral surface component resulting in an amino acid addition, substitution and/or addition in said viral surface component in a region defined by amino acids 118 to 169 and also 169 to 207 of the HBV surface antigen or functionally equivalent region wherein said variant exhibits decreased interactivity of immunological reagents to said viral surface component.

Still yet another aspect of the present invention is directed to an HBV variant comprising a mutation in an overlapping open reading frame in its genome wherein said mutation is in the B and/or C domain of DNA polymerase provided that it is not in the YMDD (SEQ ID NO 30) motif of the C domain alone; and in the overlapping region corresponding to amino acids 118 to 169 and also 169 to 207 or equivalent of HBV surface antigen and wherein said variant exhibits decreased sensitivity to a nucleotide analogue and exhibits decreased interactivity to immunological reagents specific to HBV surface antigens.

The viral variant exhibiting reduced interactivity to immunological reagents is an escape mutant since antibodies or other immunological response to HBV from a prior exposure to the virus or following vaccination are no longer effective in targeting a viral surface component since the mutation has altered a B- and/or T-cell epitope on the surface antigen.

The nucleoside analogues contemplated by the present invention include penciclovir and its oral form famciclovir as well as lamivudine (3TC). Different variants may be resistant to different nucleoside analogues. For example, in one embodiment, a variant in the B domain of HBV DNA polymerase may be resistant to famciclovir whereas a variant in the C domain may be resistant to 3TC.

The B domain is considered to comprise amino acid residues 505 to 529 of HBV DNA polymerase. This sequence is represented as follows (SEQ ID NO 24):

S/A H PI I/V LGFRK I/L PMG V/G GLSPFLLAQF

Reference to the B domain includes reference to proximal regions which includes up to about 20 amino acids on either side of the domain. Preferably, the mutation is in one or more of the following amino acids (SEQ ID NO 25):

Q/K T Y/F G R/W KLHL Y/L S/A HPI I/V LGFRK I/L PMG V/G GLSPFLLAQFTSAI C/L S

The C domain comprises amino acids 546 to 556 as follows (SEQ ID NO 26):

A/V F S/A YMDD V/L/M VLG

This includes the YMDD domain in which the methione residue is considered residue 550 (formally regarded as residue number 530). The residue numbering in this specification has been adjusted according to the new numbering system where the methione of YMDD is 550.

Reference to the C domain includes proximal regions of up to 20 amino acids either side of the domain.

The term Aresistance≅is used in its most general sense and includes total resistance or partial resistance or decreased sensitivity to a nucleoside analogue.

Preferably, the variants are in isolated form such that they have undergone at least one purification step away from naturally occurring body fluid. Alternatively, the variants may be maintained in isolated body fluid or may be in DNA form. The present invention also contemplates infectious molecular clones comprising the genome or parts thereof from a variant HBV.

Preferred mutations in the HBV DNA polymerase include one or more of Gly498Glu, Arg/Trp499Lys, Thr530Ser, Ile509Val, Phe512Leu, Val519Leu, Pro523Leu, Leu526Met, Ile533Leu, Met550Val/Ile and/or Ser559Thr. Preferred mutations in the HBV surface antigen include one or more of Asp144Glu and/or Gly145Arg. These correspond to positions 498 and 499 of DNA polymerase, respectively. More preferably, the variants contain two or more of the above-mentioned mutations.

One particular mutant HBV has the nucleotide sequence set forth in SEQ ID NO:17 and exhibits a multiphenotypic mutation rendering the DNA polymerase resistant to nucleoside analogues and an altered surface antigen such that it has reduced interactivity with antibodies to HBV surface antigen. The mutation is G498E in the DNA polymerase open reading frame as D144E and G145R in the surface antigen. This results from a double mutation in nucleotide numbers 226 and 227 of SEQ ID NO:17 to G and A. The polymerase protein of HBV is also similar to the DNA polymerase of Herpes Simplex Virus (HSV) (see FIG. 3 for alignment). A mutation (Gly841Cys) in the HSV polymerase gene was selected for in the presence of famciclovir (15). This mutation occurs in the same position as the G498E mutation of the HBV polymerase.

The present invention extends to the nucleotide sequence set forth in SEQ ID NO:17 as well as a nucleotide sequence having at least 60% similarity thereto and which carries a double mutation in the amino acid sequence of DNA polymerase and the HBV surface antigen. Accordingly, the present invention is directed to an HBV having the nucleotide sequence as set forth in SEQ ID NO:17 or a derivative thereof having a single or multiple nucleotide addition, substitution and/or deletion thereto such as a nucleotide sequence having at least 60% similarity to SEQ ID NO:17. A derivative includes parts, fragments, portions and homologues of SEQ ID NO:17. This aspect of the present invention also extends to a nucleotide sequence capable of hybridizing under low stringency conditions at 421C to SEQ ID NO:17.

Reference herein to a low stringency at 42 EC includes and encompasses from at least about 1% v/v to at least about 15% v/v formamide and from at least about 1M to at least about 2M salt for hybridisation, and at least about 1M to at least about 2M salt for washing conditions. Alternative stringency conditions may be applied where necessary, such as medium stringency, which includes and encompasses from at least about 16% v/v to at least about 30% v/v formamide and from at least about 0.5M to at least about 0.9M salt for hybridisation, and at least about 0.5M to at least about 0.9M salt for washing conditions, or high stringency, which includes and encompasses from at least about 31% v/v to at least about 50% v/v formamide and from at least about 0.01M to at least about 0.15M salt for hybridisation, and at least about 0.01M to at least about 0.15M salt for washing conditions.

Accordingly, another aspect of the present invention contemplates a variant HBV exhibiting reduced sensitivity to a nucleoside analogue and reduced interactivity to an antibody to wild-type HBV surface antigen, said HBV variant characterised by one or more of the following characteristics:

-   (i) a nucleotide sequence of its genome as set forth in SEQ ID NO:17     or a sequence having at least 60% similarity thereto; -   (ii) a nucleotide sequence capable of hybridising to SEQ ID NO:17     under low stringency conditions at 421 C; -   (iii) a mutation in an overlapping portion of open reading frames     for DNA polymerization and HBV surface antigen; and -   (iv) a mutation in the B and/or C domain of HBV DNA polymerase and     is a region corresponding to amino acids 118 to 169 and also 169 to     207 of HBV surface antigen.

According to another aspect of the present invention, there is provided a variant HBV comprising a nucleotide sequence which encodes a DNA polymerase having the amino acid sequence (SEQ ID NO:27 and SEQ ID NO:28):

X₁HPIX₂LGX₃RKX₄PMGX₅GLSX₆FLX₇AQFTSAX₈X₉ . . . X₁₀FX₁₁YX₁₂DDX₁₃VLGAX₁₄X₁₅

wherein X₁ is S or A;

-   -   X₂ is I or V;     -   X₃ is F or L;     -   X₄ is I or L;     -   X₅ is L or V or G;     -   X₆ is P or L;     -   X₇ is L or M;     -   X₈ is I or L;     -   X₉ is C or L;     -   X₁₀ is A or V;     -   X₁₁ is S or A;     -   X₁₂ is M or I or V;     -   X₁₃ is V or L or M;     -   X₁₄ is K or R; and/or     -   X₁₅ S or T;

and wherein said variant exhibits reduced sensitivity to a nucleoside sensitivity to a nucleoside analogue, such as famciclovir (penciclovir) and/or lamivudine (3TC).

Another embodiment of the present invention is directed to a variant HBV comprising a nucleotide sequence which encodes a surface antigen having at least one amino acid substitution, addition and/or deletion to amino acid residue numbers 118 to 169 and also 169 to 207 of said surface antigen which corresponds to a DNA polymerase having the amino acid sequence (SEQ ID NO:42 and SEQ ID NO:43):

X₁₆TX₁₇X₁₈X₁₉KLHLX₂₀X₂₁HPIX₂₂LGX₃RKX₄PMGX₅GLSX₆FLX₇AQFTSAX₈X₉ . . . X₁₀FX₁₁YX₁₂DDX₁₃VLGAX₁₄X₁₅

wherein: X₁₆ is Q or K;

-   -   X₁₇ is Y or F;     -   X₁₈ is G or E;     -   X₁₉ is R or W or K;     -   X₂₀ is Y or L;     -   X₂₁ is S or A;     -   X₂₂ is I or V;     -   X₃ is F or L;     -   X₄ is I or L;     -   X₅ is L or V or G;     -   X₆ is P or L;     -   X₇ is L or M;     -   X₈ is I or L;     -   X₉ is C or L;     -   X₁₀ is A or V;     -   X₁₁ is S or A;     -   X₁₂ is M or I or V;     -   X₁₃ is V or L or M;     -   X₁₄ is K or R; and/or     -   X₁₅ S or T;

and wherein said variant exhibits reduced interactivity with immunological reagents, such as an antibody, to said surface antigen.

Examples of preferred variants comprise the amino acid sequences shown in FIG. 4. An example of a particularly preferred mutant is shown in FIG. 5 (SEQ ID NO:17).

The identification of the variants of the present invention permits the generation of a range of assays to detect such variants. The detection of such variants may be important in identifying resistant variants to determine the appropriate form of chemotherapy and/or to monitor vaccination protocols.

Accordingly, another aspect of the present invention contemplates a method for determining the potential for an HBV to exhibit reduced sensitivity to a nucleoside analogue, said method comprising isolating DNA or corresponding mRNA from said HBV and screening for a mutation in the nucleotide sequence encoding HBV DNA polymerase resulting in at least one amino acid substitution, deletion and/or addition in the B domain or C domain or a region proximal thereto of said DNA polymerase wherein the presence of such a mutation is an indication of the likelihood of resistance to said nucleoside analogue.

A further aspect of the present invention provides a method for determining the potential for an HBV to exhibit reduced interactivity to antibody to HBV surface antigen, said method comprising isolating DNA or corresponding mRNA from said HBV and screening for a mutation in the nucleotide sequence encoding HBV surface antigen resulting in at least one amino acid substitution, deletion and/or addition in amino acids 118 to 169 and/or 169 to 207 of said surface antigen or a region proximal thereto of said surface antigen wherein the presence of such a mutation is an indication of the likelihood of reducing interactivity of said antibodies to said mutated surface antigen.

Preferably, the assay determines a mutation resulting in a Glu/Val519Leu substitution and/or a Leu526Met substitution and/or a Pro523Leu substitution and/or a S559T substitution, and/or Gly498Glu substitution, and/or Arg/Trp499Lys substitution.

The DNA or corresponding RNA may be assayed or alternatively the DNA polymerase or surface antigen may be screened for the mutation.

The detection according to this aspect of the invention may be any nucleic acid-based detection means, for example nucleic acid hybridisation techniques or polymerase chain reaction (PCR). The invention further encompasses the use of different assay formats of said nucleic acid-based detection means, including restriction fragment length polymorphism (RFLP), amplified fragment length polymorphism (AFLP), single-strand chain polymorphism (SSCP), amplification and mismatch detection (AMD), interspersed repetitive sequence polymerase chain reaction (IRS-PCR), inverse polymerase chain reaction (iPCR) and reverse transcription polymerase chain reaction (RT-PCR), amongst others.

The present invention extends to a range of immunologically based assays to detect variant HBV DNA polymerase or surface antigen. These assays are based on antibodies directed to naturally occurring HBV DNA polymerase or surface antigen which do not, or substantially do not, interact with the variant HBV DNA polymerase or surface antigen. Alternatively, antibodies to a variant HBV DNA polymerase or surface antigen are used which do not or substantially do not, interact with naturally occurring HBV DNA polymerase or surface antigen.

Monoclonal or polyclonal antibodies may be used although monoclonal antibodies are preferred as they can be produced in large quantity and in a homogenous form. A wide range of immunoassay techniques are available such as described in U.S. Pat. Nos. 4,016,043, 4,424,279 and 4,018,653.

The detection of amino acid variants of DNA polymerase is conveniently accomplished by reference to the consensus amino acid sequence shown in FIG. 4. The polymorphisms shown represent the variations shown in various data bases for active pathogenic HBV strains. Where an HBV variant comprises an amino acid different to what is represented, then such an isolate is considered a putative HBV variant having an altered DNA polymerase activity.

Accordingly, another aspect of the present invention contemplates a method for determining whether an HBV isolate encodes a variant DNA polymerase, said method comprising determining the amino acid sequence of its DNA polymerase directly or via a nucleotide sequence and comparing same to the amino acid sequence below (SEQ ID NO:29):

         DOMAIN A 421       430         440        450 S^(N) _(D)LSWLSLD VSAAFYH ^(I) _(P)PL HPAAMPHLL^(I) _(V) GSSGL^(S) _(D)RYVA 460         470            480           490 RLSS^(T) _(N)S^(R) _(N)N_(I)*N ^(N)Y_(H)Q^(H) _(Y) ^(G) _(R)***^(D) _(N)LH ^(D) _(N) ^(S) _(Y)CSR^(N) _(Q)LYVS L^(L) _(M)LLY^(K) _(Q)T^(Y) _(F)G^(R) _(W)               DOMAIN B 500         510        520         530 KLHL^(Y)L ^(S) _(A)HPI^(I) _(V )LGFRK^(I) _(L)PMG^(V) _(G) GLSPFLLAQF TSAI^(C) _(L) ^(A) _(S) ^(V) _(M) ^(V) _(T) ^(R) _(C)R             DOMAIN C 540         550             560 AF^(F) _(P)HC^(L) _(V) ^(A) _(V)F^(S) _(A)Y MDD^(V)L_(M)VLGA ^(K) _(R) ^(S) _(T) ^(V) _(G) ^(Q) _(E)H^(L)S_(R)E^(S) _(F)L^(F) _(Y) ^(T) _(A) ^(A) _(S)             DOMAIN D       DOMAIN E 570            580        590         600  ^(V) _(I) ^(T) _(C) ^(N) _(S) ^(F) _(V)LL^(S) _(D) ^(L) _(V)GI HLNP^(N) _(Q)KTKRW GYSLNFMGY^(V) _(I)I G

where the presence of a different amino acid from the consensus sequence indicates a putative HBV variant.

The present invention further contemplates agents which mask the nucleoside analogue resistance mutation. Such agents will be particularly useful in long term treatment by nucleoside analogues. The agents may be DNA or RNA or proteinaceous or non-proteinaceous chemical molecules. Natural product screening such as from plants, coral and microorganisms is also contemplated as a useful potential source of masking agents. The agents may be in isolated form or in the form of a pharmaceutical composition and may be administered sequentially or simultaneously with the nucleoside analogue.

The subject invention extends to kits for assays for variant HBV. Such kits may, for example, contain the reagents from PCR or other nucleic acid hybridisation technology or reagents for immunologically based detection techniques.

The present invention is further described by the following non-limiting figures and examples.

In the figures:

FIG. 1 is a diagrammatic representation showing the partially double stranded DNA HBV genome showing the overlapping open reading frames encoding surface (S), core (C), polymerase (P) and X gene.

FIG. 2 is a graphical representation showing serum biochemical (ALT) and virological (HBV DNA) profile in the transplant patient and the responses following the introduction of various antiviral treatment programs. Treatment GCV+PFF, GCV and FCV[I] and FCV[II] are described in detail in the examples. Treatment GCV+PFF is ganciclovir plus foscarnet combination (12), treatment GCV is parenteral ganciclovir maintenance therapy and treatment FCV[I] and FCV[II] is oral famciclovir therapy at a dose of 250 mg or 500 mg twice daily, respectively. The day each therapy commenced is shown in brackets. The ALT (X-X) and the HBV DNA (˜-˜) responses are plotted against time from the commencement of antiviral therapy at 6 months post-OLT. The five key time points for the sequence analysis, pre-treatment (PRE-) and days 87, 600, 816 and 1329 post antiviral treatment are shown.

FIG. 3 is a representation showing amino acid alignment of the RNA dependent DNA polymerase sequence motifs from HBV, pre-treatment with famciclovir and 370 days post-treatment (total antiviral therapy of 816 days), with the woodchuck hepatitis virus (WHV), human immunodeficiency virus (HIV), and the comparable regions with the DNA polymerase of herpes simplex virus (HSV) (13, 14). The conserved asparagine (D) and glycine (G) residues within the polymerase motifs are in bold type and the amino acid changes found after famciclovir treatment are in bold type and underlined. The location of the mutated amino acid residues within HBV polymerase are shown. The bold face underlined glycine (G) residue in the HSV polymerase becomes a cysteine (C) during penciclovir treatment (15).

FIG. 4 is a representation showing conserved regions of domain A to E (underlined) of HBV. M in YMDD is designated amino acid number 550. * indicates greater than three amino acid possibilities at this position of the consensus sequence.

FIG. 5 is a representation showing amino acid alignment of the RNA dependent DNA polymerase sequence motifs from HBV, noting the amino acid changes which have been selected for in the presence of famciclovir and 3TC. HBV concensus sequence was derived from published sequences in Genebank/Entrez. The conserved asparagine (D) and glycine (G) residues within the polymerase motifs are in bold type. The amino acid changes found after famciclovir treatment are in bold green type and underlined and after 3TC are in bold blue type and are underlined. The amino acid sequence of the HBV isolated from patient A and patient B, during famicilovir treatment and from Patient C who did not respond to famciclovir and was later treated with 3TC in which a resistance mutation was selected (3TC 2). The published 3TC changes detected by Ling et al (16) is shown in 3TC 1.

FIG. 6 is a representation showing the nucleotide sequence of an HBV variant and corresponding amino acid sequences for HBV DNA polymerase and HBV surface antigen showing in bold mutations G498E in the polymerase and D144E and G145R in the surface antigen.

EXAMPLE 1 Case Study

1. Patient A

The inventors sequenced the HBV polymerase and X open reading frames from a series of isolates from a patient who received antiviral therapy for almost 4 years following post liver transplant recurrence of HBV infection (FIG. 2).

The patient (male, aged 42 years) was transplanted because of end-stage liver failure due to chronic HBV infection. The initial post transplant course was unremarkable but by 5 months there was evidence of recurrent infection and very high levels of viral replication and deteriorating liver function (12). The histological picture was consistent with fibrosing cholestatic hepatitis. Antiviral treatment was commenced approximately 6 months post-OLT. Initially, the patient received intravenous (iv) ganciclovir (GCV; 10 mg/kg/day) in combination with iv foscarnet (PFF; 50-125 mg/kg/day; the dose depending on renal function) (12). This is the treatment of GCV+PFF described in FIG. 1 which lasted for 86 days. Maintenance iv GCV (3.3-6.7 mg/kg/day) three times per week was commenced on day 87 of antiviral treatment (GCV in FIG. 1). Oral famciclovir (250 mg, twice daily) was commenced on day 446 of therapy (FCV [I] in FIG. 1) which was increased to 500 mg twice daily (FCV [II] in FIG. 1) on day 500. The patient is currently on this treatment regime. The clinical and virological details of this patient preceding famciclovir therapy have been reported (12).

Serum samples were routinely collected and stored at −70 EC. Informed consent was obtained from the patient to use these samples for research purposes. FIG. 2 shows the alanine amino transferase (ALT) and HBV DNA levels over the entire course of antiviral treatment. The 5 samples chosen for additional studies cover a period of almost four years.

2. Patient B

Patient B was retransplanted for pre-core mutant associated HBV-related allograph loss 14 months after the initial liver transplant. Antiviral treatment with GCV (7.5 mg/kg/day) was given for 10 months and then ceased. This was followed by oral famciclovir therapy given (500 mg 3 times/day).

From patient B the entire HBV polymerase gene was sequenced from a serum HBV sample taken post-transplantation after 850 days FCV therapy. The regions encompassing the catalytic domains of the HBV polymerase were sequenced from a serum sample pretransplant prior to FCV treatment.

3. Patient C

This patient did not respond to famciclovir and was later treated with lamivudine (3TC) (6, 7) in which a resistance mutation was selected.

4. Patient D

This patient is treated with famciclovir in which resistance mutation is selected.

EXAMPLE 2 Viral Markers in Serum

Hepatitis B surface antigen (HbsAg), hepatitis B e antigen (HbeAg), anti-HBe, hepatitis B core antigen (HbcAg) specific IgG and IgM, hepatitis A specific IgM, hepatitis delta antigen and antibody, and anti-hepatitis C virus antibody were measured using commercially available immunoassays (Abbott Laboratories, North Chicago, Ill.). Only the HBV markers were positive. Hepatitis B viral DNA levels were measured and quantified using a capture hybridisation assay according to the manufacturer=s directions (Digene Diagnostics Inc., Beltsville, Md.). This patient was infected with a pre-core HBV mutant pre-OLT (12) and this status did not change post-OLT.

EXAMPLE 3 Sequencing and Cloning of HBV DNA

1. Extraction of DNA from sera: Aliquots of 50 Φl of sera were mixed with 150 Φl TE (10 mmol/L Tris-HCl (pH 7.5), 2 mmol/L EDTA), 1% w/v sodium dodecyl sulfate and 1 mg/ml pronase and incubated at 37 EC for 2 hours. DNA was deproteinised by phenol/chloroform, precipitated with isopropanol and dissolved in 25 Φl nuclease-free water.

2. Amplification of the viral polymerase and X genes by polymerase chain reaction (PCR): Oligonucleotides were synthesised by Bresatec, Adelaide, Australia. For amplification of the polymerase gene, the sense primer was 5N-GGA GTG TGG ATT CGC ACT CC-3N [SEQ ID NO:1] (nucleotides [nt] −40 to −21) and the antisense primer was 5N-GCT CCA AAT TCT TTA TA-3N [SEQ ID NO:2] (nt 2831 to 2847). For amplification of the X gene, the sense primer was 5N-CCT TTA CCC CGT TGC CCG GC-3N [SEQ ID NO:3] (nt 2055 to 2074) and the antisense primer 5N-GCT CCA AAT TCT TTA TA-3N [SEQ ID NO:4] (nt 2831 to 2847). All nt are numbered from the start of the polymerase gene. Each reaction was carried out using 5 Φl of the extracted DNA as template, 1.5 U of Taq polymerase (Perkin Elmer Cetus, Norwalk, Conn.), 1 Φmol/L of sense and antisense primers, 200 Φmol/L each of deoxynucleoside triphosphates, 50 mmol/L Kcl, 3.5 mmol/L MgCl, 10 mmol/L Tris-Hcl (pH 8.3) and 0.01% w/v gelatin. Amplification was achieved by 40 cycles of denaturation (94 EC for 1 min), annealing (55 EC for 1 min) and extension (72 EC for 1.5 min), followed by a final extension of 7 min (Perkin-Elmer Cetus, Norwalk, Conn.). The PCR product was analysed by gel electrophoresis through 1.5% w/v agarose and visualised by UV irradiation after staining with ethidium bromide.

3. Sequencing of the polymerase and X genes of HBV DNA: The specific amplified product was purified using Geneclean II (BIO 101 Inc., La Jolla, Calif.) and directly sequenced using Sequenase version 2.0 (United States Biochemical Corp., Cleveland, Ohio). The PCR primers were used as sequencing primers and internal primers were additionally synthesised to sequence the internal regions of the PCR products. The following internal and sequencing primers were used 5N-GCC GCG TCG CAG AAG ATC TCA AT-3N [SEQ ID NO:5] (nt 104-126), 5N-GGT TCT ATC CTA ACC TTA CC-3N [SEQ ID NO:6] (nt 341-360), 5N-GCC TCA TTT TGT GGG TCA CCA TA-3N [SEQ ID NO:7] (nt 496-518), 5N-TGG GGG TGG AGC CCT CAG GCT-3N [SEQ ID NO:8] (nt 731-751), 5N-CAC AAC ATT CCA CCA AGC TC-3N [SEQ ID NO:9] (nt 879-899), 5N-AAA TTC GCA GTC CCC AAC-3N [SEQ ID NO:10] (nt 1183-1195), 5N-GTT TCC CTC TTC TTG CTG T-3N [SEQ ID NO:11] (nt 1429-1447), 5N-TTT TCT TTT GTC TTT GGG TAT-3N [SEQ ID NO:12] (nt 1683-1703) 5N-CCA ACT TAC AAG GCC TTT CTG-3N [SEQ ID NO:13] (nt 1978-1999), 5N-CAT CGT TTC CAT GGC TGC TAG GC-3N [SEQ ID NO:14] (nt 2239-2262).

4. Cloning of the HBV polymerase gene into pUC18: Due to the small amount of HBV DNA in the samples, the region encompassing nt 1429 to 1703 from the HBV polymerase gene were amplified by PCR using the primers-5N-GTT TCC CTC TTC TTG CTG T-3N [SEQ ID NO:15] (nt 1429-1447) and 5N ATA CCC AAA GAC AAA AGA AAA-3N [SEQ ID NO:16] (nt 1703-1683), before cloning. The DNA was purified with Geneclean II and ligated using T4 DNA ligase (New England Biolabs, Beverly, Mass.) into a Sma I—digested dephosphorylated pUC18 plasmid (Pharmacia Biotech, NJ). Clones were directly sequence as above.

EXAMPLE 4 DNA Polymerase Assay

Samples of serum (100 Φl) were applied to a 20% w/v sucrose cushion in THE (20 mmol/L Tris-HCl pH 7.4, 150 mmol/L NaCl₂ 1 mmol/L EDTA) and centrifuged at 200,000 g for 3 hr at 101 C using an SW41 rotor in a Beckman Model L8 ultracentrifuge. The pellet was resuspended in 50 mmol/L TRIS-HCl pH 7.5 containing 1.5% v/v Triton-X100, 100 mmol/L Kcl and 0.01% v/v 2-mercaptoethanol and allowed to stand overnight at 41 C. Small aliquots of the suspension were assayed for endogenous HBV DNA polymerase activity essentially as described by Price et al (16). Each assay was performed in a total volume of 30 Φl which contained 20 Φl of the partly purified HBV and (final concentrations) 30 mmol/L Tris-HCl pH 7.5, 30 mmol/L MgCl₂, 10 Φmol/L each dATP, dTTP and dGTP, and 0.01 ΦM [α-³²P]-dCTP (3,000 Ci/mmol) (Dupont NEN, Boston, Mass.). To test for penciclovir triphosphate (PCV-TP) sensitivity, paired assays were performed on each sample, with an excess (100 Φmol/L penciclovir-triphosphate included in the reaction mixture in one assay of each pair. After 2 hr at 371 C, reactions were stopped by spotting 20 Φl aliquots of each reaction mix onto 25 mm diameter glass fibre discs (Advantex, Tokyo, Japan) which had been pre-soaked in 10% w/v trichloroacetic acid (TCA). Discs were dried before washing in ice-cold 10% w/v TCA containing 10 mmol/L sodium pyrophosphate. Three further 10 min washes in cold 5% v/v TCA followed. The washed discs were finally rinsed in absolute ethanol, air dried, and counted for radioactivity. Inhibition of HBV DNA polymerase activity by PCV-TP was expressed as the percentage difference in activity in the assay mix containing PCV-TP compared to the matched control. Because of limited sample amounts, it was not possible to standardize enzyme activity or to perform replicate assays. Despite the inherent variability of the assay, a general time related decrease in sensitivity of the HBV DNA polymerase to PCV-TP was evident (see Table 1).

EXAMPLE 5 Effect of Antiviral Therapy

Upon commencement of the antiviral treatment strategy GCV+PFF, the level of HBV DNA post-OLT decreased from over 100,000 pg/ml to 10,800 pg/ml by day 87 (FIG. 1). This reduction in viraemia was associated with clinical, biochemical and histological improvement (12). Maintenance famciclovir therapy (treatment GCV) resulted in fluctuating levels of HBV DNA over the ensuring 359 days with two peaks of HBV DNA observed. The switch to oral famciclovir on day 446 was also associated with a rise in HBV DNA, but this was likely to have been the result of insufficient dosing (FCV[I] in FIG. 2) rather than a breakthrough in treatment. Following dose increase to FCV [II] on day 500, there was a decrease in HBV DNA. However, the level of HBV DNA gradually rose over time from 3,000 pg/ml on day 600 (154 days of famciclovir), to 8,800 pg/ml on day 816 (370 days famciclovir), peaking at 29,000 pg/ml on day 1302 (856 days of famciclovir), then stabilising at around 12,000 pg/ml on day 1329 (883 days of famciclovir). A students test of the DNA levels during the treatment period from days 816 to days 1329, revealed statistically significant rise. There was a 1.5 to 2 fold rise in ALT levels over the same time interval (FIG. 2) and no change in clinical status.

EXAMPLE 6 Nucleotide Changes

The X and the polymerase genes of HBV were sequenced at five time points (FIG. 2). During almost 4 years of the antiviral therapy there were no changes in the X gene compared to the pretreatment sequence. However, there were 5 nt changes detected in the polymerase gene from day 816 and day 1329 samples (Table 1). These changes were detected in separate independent PCR amplifications; furthermore the mutations were detected by sequencing both strands and are therefore unlikely to be the result of PCR generated errors. The nt changes in the polymerase gene were first detected after 816 days of treatment, when the patient had been treated with famciclovir for 370 days. However, only two nt changes, at positions 1498 and 1519 resulted in amino acid changes, Val 519-Leu and Leu 526-Met, respectively. These two nt changes appeared concurrently. At 816 days, three different nt (C,G,T) were detected at position 1498 (all of which would result in a Val to Leu change). After 1329 days post-treatment, thymidine was the dominant species at nt 1498. The amino acid changes at 816 and 1329 days post treatment coincided with reduced serum HBV DNA polymerase sensitivity to PCV-TP (Table 1). These nt changes were not found in 6 patients with post-OLT recurrent HBV infection who were not undergoing FCV therapy.

The region encompassing the nt mutations which gave rise to amino acid changes from the sample taken at 1329 days was cloned and sequenced. Three quasi-species were detected. Seventy-five percent (15/20) of the clones contained both the 1498 and 1519 mutations which occurred together. Pretreatment non-mutated sequences were detected in 3/20 of the clones. A further mutation at nt 1511, which would result in a proline to leucine change at position 523, was detected in 2/20 of the clones. This mutation was not detected with the two dominant mutations, 1498 (Val 519-Leu) and 1519 (Leu 526-Met), nor was it detected by direct PCR sequencing, indicating it probably occurs at a low frequency. Viral DNA from the sample obtained at 600 days (150 days of FCV treatment) was also cloned and sequenced; however, only the pre-treatment sequences were detected.

EXAMPLE 7 Nucleotide Changes in Patients B, C and D

The amino acid changes in HBV isolated from patients B and C are shown in FIG. 5, and from patient D is shown in FIG. 6. In FIG. 5, patient A is the same as shown in FIG. 3.

Patient B was undergoing long term famciclovir treatment (>850 days). The amino acid change selected during famciclovir treatment is shown as HBV (patient B) in FIG. 5. Patient C did not respond to famciclovir and was later treated with 3TC (lamivudine [6,7]). The HBV isolated during FCV treatment from patient C, is shown as HBV (patient C-FCV). All 3TC resistance mutations which developed during treatment with 3TC is shown as HBV (patient C-3TC). The sequence analysis showed a mutation (Thr-Ser substitution) in the HBV polymerase gene near the C domain but no mutation was initially detected in the YMDD motif A mutation of Met 550 to Ile in the YMDD motif was detected from HBV isolated 32 days (333 days post treatment) after the HBV containing the Thr-Ser substitution was isolated.

EXAMPLE 8 Escape Mutants

Using the method hereinbefore described, HBV variants are screened for escape mutations. These are mutations in surface components such as the HBV surface antigen which reduce the interactivity of the surface component to antibodies or other immunological reagents. Given the overlapping open reading frame of HBV genome, a single mutation may have multiphenotypic consequences. For example, a mutation in the HBV DNA polymerase may also have an affect on the HBV surface antigen.

Preferred mutations in the HBV surface antigen are in amino acids 118 to 169 and/or 169 to 207 such as D144E or G145R. These correspond to DNA polymerase mutations G498E and V499L.

A particularly preferred escape mutant and nucleoside analogue resistant mutant has a nucleotide sequence set forth in FIG. 6 with corresponding amino acid sequences for the DNA polymerase and surface antigen.

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.

TABLE 1 Nucleotide mutations in the polymerase gene and the resulting amino acid changes during antiviral therapy Inhibition of Days of Days of HBV DNA antiviral famciclovir POLYMERASE GENE Polymerase by treatment treatment nt 297 nt 1498 nt1511* nt 1519 nt 2008 nt 2331 PCV-TP** Pretreatment   NR*** T G C C C G 40%  87 NR — — — — — — NA****  600 154 — — — — — — 30%  816 370 — G, T, C — A — —  0% 1329 883 C T T A A A  0% Amino acid change None Val 519-Leu Pro 523-Leu Leu 526-Met None None The dashes indicate no change from the pre-treatment nucleotide. *The mutation was only detected after cloning the PCR product after 1329 days of antiviral treatment. It occurred at a low frequency and was present in only 10% of clones. **The percentage inhibition of HBV DNA polymerase by PCV-TP in the in vitro assay as described in the Methods section. ***NR—not relevant ****NA—not assessable

BIOGRAPHY

1. Summers J, Mason W. Cell (1982) 29: 403-415.

2. Vere Hodge R. A. Antiviral Chem Chemother (1993) 4:67-84.

3. Boyd M R et al Antiviral Chem Chemother. (1987) 32: 358-363.

4. Kruger T et al Hepatology (1994) 22: 219A.

5. Main J et al. J. Viral Hepatitis (1996) 3:211-215.

6. Severini A et al Antimicrobial Agents Chemother (1995) 39: 1430-1435.

7. Dienstag J L et al New England J Med (1995) 333: 1657-1661.

8. Shaw T, et al. Antimicrobiol Agents Chemother (1994) 38:719-723.

9. Shaw T, et al. Hepatology (1996) 24: in press.

10. Tsiquaye K N, et al. J. Med Virol (1994) 42: 306-310.

11. Boker K H W, et al. Transplantation (1994) 57: 1706-1708.

12. Angus P, et al. J. Gastroenterol Hepatol (1993) 8: 353-357.

13. Poch O, et al. EMBO J. (1989) 8: 3867-3874.

14. Delarue M, et al. Protein Engineering (1990) 3: 461-467.

15. Chiou H C, et al. Antiviral Chem Chemother (1995) 6: 281-288.

16. Ling R, et al. Hepatology (1996) 24: 711-713.

17. Price P M, et al. Hepatology 1992 16: 8-13. 

We claim:
 1. An isolated HBV mutant, comprising one or more mutations in the gene encoding the HBV polymerase resulting in decreased sensitivity to a nucleoside analogue compared to a wild-type HBV, wherein said mutation(s) result(s) in at least one amino acid addition, substitution and/or deletion in the A domain corresponding to amino acid residues 421-436 of a wild-type HBV polymerase and/or in the D domain corresponding to amino acid residues 576-588 of a wild-type HBV polymerase and/or in the E domain corresponding to amino acid residues 592-600 of a wild-type HBV polymerase, or in a region proximal thereto.
 2. An isolated HBV mutant according to claim 1, comprising one or more mutations in the gene encoding the HBV polymerase resulting in decreased sensitivity to a nucleoside analogue compared to a wild-type HBV, wherein said mutation(s) result(s) in at least one amino acid addition, substitution and/or deletion in the A domain corresponding to amino acid residues 421-436 of a wild-type HBV polymerase.
 3. An isolated HBV mutant according to claim 1, comprising one or more mutations in the gene encoding the HBV polymerase resulting in decreased sensitivity to a nucleoside analogue compared to a wild-type HBV, wherein said mutation(s) result(s) in at least one amino acid addition, substitution and/or deletion in the D domain corresponding to amino acid residues 576-588 of a wild-type HBV polymerase.
 4. An isolated HBV mutant according to claim 1, comprising one or more mutations in the gene encoding the HBV polymerase resulting in decreased sensitivity to a nucleoside analogue compared to a wild-type HBV, wherein said mutation(s) result(s) in at least one amino acid addition, substitution and/or deletion in the E domain corresponding to amino acid residues 592-600 of a wild-type HBV polymerase.
 5. A method for determining the potential for an HBV to exhibit reduced sensitivity to a nucleoside analogue, said method comprising isolating DNA or corresponding mRNA from said HBV and screening for one or more mutation(s) in the nucleotide sequence encoding HBV DNA polymerase resulting in at least one amino acid substitution, deletion and/or addition in the D domain or E domain or a region proximal thereto of said DNA polymerase wherein the presence of such a mutation is an indication of the likelihood of resistance to said nucleoside analogue.
 6. A method for determining whether an HBV isolate encodes a variant DNA polymerase, said method comprising determining the amino acid sequence of its DNA polymerase directly or via a nucleotide sequence and comparing same to the amino acid sequence below (SEQ ID NO:29):               DOMAIN A 421       430         440        450 S^(N) _(D)LSWLSLD VSAAFYH ^(I) _(P)PL HPAAMPHLL^(I) _(V) GSSGL^(S) _(D)RYVA 460         470            480          490 RLSS^(T) _(N)S^(R) _(N)N_(I)*N ^(N)Y_(H)Q^(H) _(Y) ^(G) _(R)***^(D) _(N)LH ^(D) _(N) ^(S) _(Y)CSR^(N) _(Q)LYVS L^(L) _(M)LLY^(K) _(Q)T^(Y) _(F)G^(R) _(W)              DOMAIN B 500         510        520         530 KLHL^(Y)L ^(S) _(A)HPI^(I) _(V )LGFRK^(I) _(L)PMG^(V) _(G) GLSPFLLAQF TSAI^(C) _(L) ^(A) _(S) ^(V) _(M) ^(V) _(T) ^(R) _(C)R              DOMAIN C 540         550             560 AF^(F) _(P)HC^(L) _(V) ^(A) _(V)F^(S) _(A)Y MDD^(V)L_(M)VLGA ^(K) _(R) ^(S) _(T) ^(V) _(G) ^(Q) _(E)H^(L)S_(R)E^(S) _(F)L^(F) _(Y) ^(T) _(A) ^(A) _(S)              DOMAIN D      DOMAIN E 570            580        590         600  ^(V) _(I) ^(T) _(C) ^(N) _(S) ^(F) _(V)LL^(S) _(D) ^(L) _(V)GI HLNP^(N) _(Q)KTKRW GYSLNFMGY^(V) _(I)I G

where the presence of a different amino acid from the consensus sequence in the D or E domain indicates a putative HBV mutant.
 7. The method according to one of claim 5 or claim 6, wherein the screening for a mutation or determining the amino acid sequence comprises sequencing said isolated HBV DNA or corresponding DNA.
 8. The method according to one of claim 5 or claim 6, wherein the screening for a mutation or determining the amino acid sequence comprises a PCR method or PCR-based method.
 9. The method according to one of claim 5 or claim 6, wherein the screening for a mutation or determining the amino acid sequence comprises a hybridization method.
 10. A method for determining whether an HBV isolate encodes a variant DNA polymerase said method comprising determining the amino acid sequence of the A domain (corresponding to amino acid residues 421-436) or a region proximal thereto (corresponding to amino acid residues 437-456) directly or via a nucleotide sequence and comparing same to the A domain or the region proximal thereto of the following amino acid sequence (SEQ ID NO:29):               DOMAIN A 421       430         440        450 S^(N) _(D)LSWLSLD VSAAFYH ^(I) _(P)PL HPAAMPHLL^(I) _(V) GSSGL^(S) _(D)RYVA 460         470            480          490 RLSS^(T) _(N)S^(R) _(N)N_(I)*N ^(N)Y_(H)Q^(H) _(Y) ^(G) _(R)***^(D) _(N)LH ^(D) _(N) ^(S) _(Y)CSR^(N) _(Q)LYVS L^(L) _(M)LLY^(K) _(Q)T^(Y) _(F)G^(R) _(W)              DOMAIN B 500         510        520         530 KLHL^(Y)L ^(S) _(A)HPI^(I) _(V )LGFRK^(I) _(L)PMG^(V) _(G) GLSPFLLAQF TSAI^(C) _(L) ^(A) _(S) ^(V) _(M) ^(V) _(T) ^(R) _(C)R              DOMAIN C 540         550             560 AF^(F) _(P)HC^(L) _(V) ^(A) _(V)F^(S) _(A)Y MDD^(V)L_(M)VLGA ^(K) _(R) ^(S) _(T) ^(V) _(G) ^(Q) _(E)H^(L)S_(R)E^(S) _(F)L^(F) _(Y) ^(T) _(A) ^(A) _(S)             DOMAIN D       DOMAIN E 570          580          590         600  ^(V) _(I) ^(T) _(C) ^(N) _(S) ^(F) _(V)LL^(S) _(D) ^(L) _(V)GI HLNP^(N) _(Q)KTKRW GYSLNFMGY^(V) _(I)I G


11. A method for determining whether an HBV isolate encodes a variant DNA polymerase according to claim 10 said method comprising determining the amino acid sequence of the D domain (corresponding to amino acid residues 576-588) or a region proximal thereto directly or via a nucleotide sequence and comparing same to the D domain or the region proximal thereto of the following amino acid sequence (SEQ ID NO:29):                DOMAIN A 421       430         440        450 S^(N) _(D)LSWLSLD VSAAFYH ^(I) _(P)PL HPAAMPHLL^(I) _(V) GSSGL^(S) _(D)RYVA 460         470            480          490 RLSS^(T) _(N)S^(R) _(N)N_(I)*N ^(N)Y_(H)Q^(H) _(Y) ^(G) _(R)***^(D) _(N)LH ^(D) _(N) ^(S) _(Y)CSR^(N) _(Q)LYVS L^(L) _(M)LLY^(K) _(Q)T^(Y) _(F)G^(R) _(W)              DOMAIN B 500         510        520         530 KLHL^(Y)L ^(S) _(A)HPI^(I) _(V )LGFRK^(I) _(L)PMG^(V) _(G) GLSPFLLAQF TSAI^(C) _(L) ^(A) _(S) ^(V) _(M) ^(V) _(T) ^(R) _(C)R              DOMAIN C 540         550             560 AF^(F) _(P)HC^(L) _(V) ^(A) _(V)F^(S) _(A)Y MDD^(V)L_(M)VLGA ^(K) _(R) ^(S) _(T) ^(V) _(G) ^(Q) _(E)H^(L)S_(R)E^(S) _(F)L^(F) _(Y) ^(T) _(A) ^(A) _(S)             DOMAIN D       DOMAIN E 570          580          590         600  ^(V) _(I) ^(T) _(C) ^(N) _(S) ^(F) _(V)LL^(S) _(D) ^(L) _(V)GI HLNP^(N) _(Q)KTKRW GYSLNFMGY^(V) _(I)I G


12. A method for determining whether an HBV isolate encodes a variant DNA polymerase according to claim 10 said method comprising determining the amino acid sequence of the E domain (corresponding to amino acid residues 592-600) or a region proximal thereto directly or via a nucleotide sequence and comparing same to the E domain or the region proximal thereto of the following amino acid sequence (SEQ ID NO:29)               DOMAIN A 421       430         440        450 S^(N) _(D)LSWLSLD VSAAFYH ^(I) _(P)PL HPAAMPHLL^(I) _(V) GSSGL^(S) _(D)RYVA 460         470            480          490 RLSS^(T) _(N)S^(R) _(N)N_(I)*N ^(N)Y_(H)Q^(H) _(Y) ^(G) _(R)***^(D) _(N)LH ^(D) _(N) ^(S) _(Y)CSR^(N) _(Q)LYVS L^(L) _(M)LLY^(K) _(Q)T^(Y) _(F)G^(R) _(W)              DOMAIN B 500         510        520         530 KLHL^(Y)L ^(S) _(A)HPI^(I) _(V )LGFRK^(I) _(L)PMG^(V) _(G) GLSPFLLAQF TSAI^(C) _(L) ^(A) _(S) ^(V) _(M) ^(V) _(T) ^(R) _(C)R              DOMAIN C 540         550             560 AF^(F) _(P)HC^(L) _(V) ^(A) _(V)F^(S) _(A)Y MDD^(V)L_(M)VLGA ^(K) _(R) ^(S) _(T) ^(V) _(G) ^(Q) _(E)H^(L)S_(R)E^(S) _(F)L^(F) _(Y) ^(T) _(A) ^(A) _(S)             DOMAIN D       DOMAIN E 570          580          590         600  ^(V) _(I) ^(T) _(C) ^(N) _(S) ^(F) _(V)LL^(S) _(D) ^(L) _(V)GI HLNP^(N) _(Q)KTKRW GYSLNFMGY^(V) _(I)I G


13. The method according to claim 10, wherein the determining comprises screening for a mutation comprises sequencing said isolated HBV DNA or corresponding DNA.
 14. The method according to claim 10, wherein the determining comprises screening for a mutation comprises a PCR method or PCR-based method.
 15. The method according to claim 10, wherein the determining comprises screening for a mutation comprises a hybridization method.
 16. HBV isolate encoding a variant DNA polymerase as detected by the method of any one of the claims 10-12.
 17. A kit for assays for detecting a HBV isolate according to claim 16 comprising one or more reagents chosen from the group consisting of nucleic acid hybridisation technology as PCR and reagents for immunologically based detection techniques. 